CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) ...
Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
Acute kidney injury (AKI), previously called acute renal failure, is when the kidneys are suddenly unable to filter waste products from the blood. This condition can develop slowly or quickly, and ...
A substantial proportion of patients admitted to hospitals in Italy experienced acute kidney injury (AKI), which was associated with worsened in-hospital mortality outcomes, longer hospital stays, and ...
CalciMedica shares fell after the company stopped its Phase 2 KOURAGE trial for Auxora due to safety concerns.
Violin MD on MSN
How one harmless snack led to sudden kidney failure
A Seemingly Innocent Dietary Choice Turned Into A Dangerous Trigger For Acute Kidney Failure, As Medical Investigators Unraveled How A Common Food Item Placed Extreme Strain On Renal Function And ...
Proton pump inhibitors (PPIs) do not appear to worsen kidney function compared with the histamine 2 receptor blocker ranitidine based on two measures, a large cohort study from Spain finds. In fact, ...
Investing.com -- CalciMedica Inc. (NASDAQ:CALC) stock plunged 80% Wednesday after the company announced it was discontinuing its Phase 2 KOURAGE clinical trial for acute kidney injury following safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results